Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method and composition for altering a b cell mediated pathology

A technology of B cells and compositions, applied in the field of immunology and immunotherapy, can solve problems such as changing chimeric idiotype proteins

Inactive Publication Date: 2006-09-06
FAVRILLE
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the use of baculoviruses to express chimeric idiotype proteins for use as immunotherapeutics to alter B-cell pathologies such as B-cell malignancies and autoimmune diseases has not been demonstrated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method and composition for altering a b cell mediated pathology
  • Method and composition for altering a b cell mediated pathology
  • Method and composition for altering a b cell mediated pathology

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0162] In the following description, reference will be made to various methods known to those skilled in the fields of immunology, cell biology, and molecular biology. Publications and other materials describing such known methods referred to are incorporated herein by reference in their entirety, as if they were described in full.

[0163] 1. Tissue processing for identification and cloning of non-Hodgkin's lymphoma idiotype (ID):

[0164] Under aseptic conditions, according to a clinically specified method, a biopsy is performed on a tumor sample obtained from a peripheral lymph node, and the sample is used to produce a patient's idiotype-specific chimeric immunoglobulin recombinant protein. Store the remaining lymph node biopsy material in the tissue cell bank in liquid nitrogen for future use.

[0165] a. Cell separation: A single cell suspension of the patient's lymph node biopsy sample is obtained by forcing the patient's biopsy lymphoma tissue to pass through a disposable 0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a method for altering a B cell mediated pathology in a patient. This method comprises administering a composition comprising at least one and / or two chimeric proteins. Each chimeric protein comprises at least a portion of either the Valpha or Vbeta region of a TCR from particular B cells from a patient having a B cell mediated pathology, and an immunoglobulin constant region. The genes encoding Valpha and / or Vbeta regions and the genes encoding immunoglobulin constant regions are isolated and inserted into an expression vector. The chimeric proteins are produced by introducing the expression vectors into insect cell lines. The chimeric proteins are purified using antibody affinity columns, and then chemically conjugated to an immunogenic carrier, keyhole-limpet hemocyanin (KLH). Since the conjugates comprises chimeric proteins made specifically from particular B cells from a patient having B cell mediated pathology, when it is administered to such a patient, with or without a cytokine, such as granulocyte-macrophage-CSF, or a chemokine, it can induce immune responses to alter such a B cell mediated pathology.

Description

[0001] Related application [0002] This application requires U.S. Provisional Application No. 60 / 224,723 entitled "Method for producing an Idiotypic Vaccine", entitled "ExpressionVectors for Production of Recombinant Immunoglobulin (ExpressionVectors for Production of Recombinant Immunoglobulin) Carrier)" U.S. Provisional Application No. 60 / 224,722 and U.S. Provisional Application No. 60 / 279,079 entitled "Method and Composition for Altering a B Cell Mediated Pathology" Priority of the number. Invention field [0003] The present invention generally relates to the fields of immunology and immunotherapy. More specifically, the present invention relates to methods and compositions for altering B cell-mediated pathologies such as B cell malignancies and / or autoimmune diseases. Background of the invention [0004] The immune system produces both antibody-mediated and cell-mediated responses. Each type of immune...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/395A61K39/385A61P37/00A61P35/00C12N15/866C12N5/10C07K16/00G01N33/68C12N15/09A61K38/00A61K38/17A61K39/00A61K47/42A61P1/16A61P3/10A61P5/14A61P17/00A61P25/00A61P37/02A61P37/06C07K16/46C07K19/00
CPCA61K39/0005A61K38/1709A61K2039/585A61K2039/6081C07K2319/30A61P1/16A61P3/10A61P5/14A61P17/00A61P25/00A61P35/00A61P37/00A61P37/02A61P37/06A61K38/16
Inventor D·P·戈德R·J·肖佩斯
Owner FAVRILLE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products